Search research articles
Contact Us
Filters
Showing results (81-90 of 533) with videos related to
Page
of 54
Sort By:
Praxis
|
July 9, 1998
[Systemic therapy of low malignancy non-Hodgkin lymphomas]
B Wörmann, C Buske, W Hiddemann
Der Internist
|
May 8, 2012
[Sport as therapy for internal diseases]
H Löllgen, W Hiddemann, K Werdan
Deutsche Medizinische Wochenschrift (1946)
|
April 15, 2005
[Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches]
K Spiekermann, W Hiddemann, S Schnittger
Medizinische Klinik (Munich, Germany : 1983)
|
May 2, 1998
[Clinical studies in oncology. Relevance, design, ethical considerations]
B Wörmann, G Wulf, W Hiddemann
Praxis
|
March 19, 1996
[Therapy of low-grade non-Hodgkin lymphomas]
W Hiddemann, M Unterhalt, B Wörmann
Deutsche Medizinische Wochenschrift (1946)
|
June 12, 2009
[Hematology 2009]
M Dreyling, K Spiekermann, W Hiddemann
Leukemia Research
|
January 1, 1991
Reversible leukaemic regrowth under GM-CSF treatment after chemotherapy for AML
M Koenigsmann, W Hiddemann, T Büchner
Annals of Hematology
|
December 12, 2003
Mantle cell lymphoma: established therapeutic options and future directions
G Lenz, M Dreyling, W Hiddemann
Der Internist
|
August 10, 2000
[Palliative psychooncology--demand and methods. Beginning anew at the end?]
U Gruber, T Vollmer, W Hiddemann
British Journal of Haematology
|
July 11, 2000
Prognostic significance of cytogenetics in relapsed acute myeloid leukaemia
W Kern, C Schoch, W Hiddemann
Page
of 54
Search research articles
Search
Showing results (81-90 of 533) with videos related to
Sort By:
Page
of 54
Praxis
|
July 9, 1998
[Systemic therapy of low malignancy non-Hodgkin lymphomas]
B Wörmann, C Buske, W Hiddemann
Der Internist
|
May 8, 2012
[Sport as therapy for internal diseases]
H Löllgen, W Hiddemann, K Werdan
Deutsche Medizinische Wochenschrift (1946)
|
April 15, 2005
[Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches]
K Spiekermann, W Hiddemann, S Schnittger
Medizinische Klinik (Munich, Germany : 1983)
|
May 2, 1998
[Clinical studies in oncology. Relevance, design, ethical considerations]
B Wörmann, G Wulf, W Hiddemann
Praxis
|
March 19, 1996
[Therapy of low-grade non-Hodgkin lymphomas]
W Hiddemann, M Unterhalt, B Wörmann
Deutsche Medizinische Wochenschrift (1946)
|
June 12, 2009
[Hematology 2009]
M Dreyling, K Spiekermann, W Hiddemann
Leukemia Research
|
January 1, 1991
Reversible leukaemic regrowth under GM-CSF treatment after chemotherapy for AML
M Koenigsmann, W Hiddemann, T Büchner
Annals of Hematology
|
December 12, 2003
Mantle cell lymphoma: established therapeutic options and future directions
G Lenz, M Dreyling, W Hiddemann
Der Internist
|
August 10, 2000
[Palliative psychooncology--demand and methods. Beginning anew at the end?]
U Gruber, T Vollmer, W Hiddemann
British Journal of Haematology
|
July 11, 2000
Prognostic significance of cytogenetics in relapsed acute myeloid leukaemia
W Kern, C Schoch, W Hiddemann
Page
of 54